| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study |
| 18 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocean 1181 LLC ... |
| 13 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 10, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Agenus Inc. (the "Company") approved a special, one-time performance-based stock option award to Garo H. Armen, Ph.D., the Company’s Chairman a... |
| 11 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer |
| 13 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 13, 2026, by and among Agenus Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Inve... |
| 06 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR ... |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Agenus Inc. (the “Company”) held its Annual Meeting of Stockholders on June 16, 2026 (the “Annual Meeting”). A total of 27,098,077 shares of common stock, representing 65.24% of the shares outstanding and eligible to vote and constitutin... |
| 15 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026. |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development |
| 26 Mar 2026 |
8-K: Other Events
On March 24, 2026, the United States District Court for the District of Massachusetts issued a Memorandum and Order in Byron Olsen, Individually and on Behalf of All Others Similarly Situated v. Agenus Inc., Garo H. Armen, Christine M. K... |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized |
| 16 Jan 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +1 more
On January 15, 2026, Agenus Inc. (the “Company”) and its wholly-owned subsidiary Agenus West, LLC (“Agenus West” and together with the Company, “Agenus”) closed the previously announced transaction (the “Transaction”) with Zydus Pharmace... |
| 14 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective January 8, 2026, Agenus Inc.'s (the “Company”) Board of Directors appointed Dr. Garo Armen, the Company's current Chairman and Chief Executive Officer to serve as the Company's interim Chief Financial Officer ("CFO") and Princi... |
| 08 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders
On January 3, 2026, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into an amendment and release agreement (the “Amendment Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) relat... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
France grants reimbursed access with patients having commenced treatment |
| 09 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 8, 2025, Agenus Inc. (“Agenus”) entered into a Promissory Note Agreement (the “Note”) with Zydus Pharmaceuticals (USA) Inc. (“Zydus”), a wholly owned subsidiary of Zydus Lifesciences Limited, for up to $10,000,000 (the “Princi... |
| 23 Sep 2025 |
8-K: Other Events
As previously announced on June 3, 2025, the Company and Zydus Pharmaceuticals (USA) Inc. entered agreements pursuant to which, (i) under an asset purchase agreement Zydus will acquire assets comprising the Company’s manufacturing operat... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Agenus Inc. (the “Company”) held its Annual Meeting of Stockholders on June 17, 2025 (the “Annual Meeting”). A total of 16,711,637 shares of common stock, representing 61.5% of the shares outstanding and eligible to vote and constituting... |
Loading...